Article Information
History
- May 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Peter Czuppon1,5 (peter.czuppon{at}upmc.fr),
- Florence Débarre1 (florence.debarre{at}normalesup.org),
- Antonio Gonçalves2 (antonio.goncalves{at}inserm.fr),
- Olivier Tenaillon2 (olivier.tenaillon{at}inserm.fr),
- Alan S Perelson3 (asp{at}lanl.gov),
- Jérémie Guedj2 (jeremie.guedj{at}inserm.fr) and
- François Blanquart4 (francois.blanquart{at}college-de-france.fr)
- 1 Sorbonne Université;
- 2 Université de Paris, INSERM;
- 3 Los Alamos National Laboratory;
- 4 Collège de France
- ↵* Corresponding author; email: peter.czuppon{at}upmc.fr
Posted May 12, 2020.
Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the targeted mechanism
